PYPD reported Q1 2026 results this morning — and the short-selling community has already been voting with its feet ahead of the print.
The most striking move this week is in short positioning. Short interest has dropped 27% over five days to just 0.15% of the free float. That caps a dramatic unwind from mid-April, when estimated short shares peaked near 194,000 — roughly eight times today's level. The retreat accelerated through late April and into early May, with shares short nearly halving between April 29 and May 12 alone. Whatever pressure had been building ahead of Q1, it has largely gone.
The borrow market reinforces that picture. Cost to borrow has eased to 6.9%, down 13% on the week and more than 58% from the highs seen in February and March, when it was running above 16%. Availability is wide open at this level — there is no tightness in the lending pool, and the ORTEX short score of 30.3 has drifted lower all week, reflecting the reduction in bearish positioning. Days-to-cover is less than one day, so even the remaining short base carries no meaningful squeeze risk. Put/call ratio has nudged up to 1.09, slightly above its 20-day mean of 0.92, but the z-score of 0.9 puts that well within normal range — options traders are marginally cautious, not alarmed.
On the Street, the picture is uniformly constructive — though the data is dated. The most recent analyst action on record is HC Wainwright reiterating Buy with a $13 target in February, following Q4 results. Roth Capital holds Buy at $9 and Craig-Hallum at $13, with both having trimmed targets in the second half of 2025. The consensus mean target of $12.25 implies more than 168% upside to the current $4.56 close — a gap that reflects both the binary nature of the D-PLEX100 regulatory path and the micro-cap risk premium. The EPS surprise factor score ranks in the 80th percentile, and today's Q1 beat — EPS of -$0.35 against an estimate of -$0.43 — keeps that streak alive. The bull case centres on FDA approval of D-PLEX100 in Q4 2026 via the PLEX drug-delivery platform; the bear case hinges on whether the company can clear a pre-approval inspection and fund operations past 2026 without a dilutive raise.
Institutional ownership is concentrated and recently active. Aurum Ventures holds 18.6% and added 467,000 shares as of the March quarter. Aigh Capital Management added 775,000 shares in the same period and now holds 8.4% — the largest single disclosed purchase by a financial holder in recent filings. Xenia Venture Capital also added 512,000 shares to reach 8.3%. Together, the top three holders control more than 35% of reported shares. That concentration matters: thin float, a largely locked-up share register, and a binary regulatory catalyst is a combination that can drive sharp moves in either direction on a single piece of FDA news.
The next scheduled earnings call is August 12. Between now and then, the key watch point is any disclosure from PolyPid on the timeline for FDA pre-approval inspection scheduling — the event the bear case identifies as the primary bottleneck on the path to commercial approval.
See the live data behind this article on ORTEX.
Open PYPD on ORTEX →ORTEX Market Intelligence content is generated by AI from a snapshot of ORTEX's proprietary data. Content is informational only and does not constitute investment advice.
